Table 5.
SYRCLE Risk of Bias for animal studies.
| Author, year | Sequence generation | Baseline characteristics | Allocation concealment | Random Housing | Blinding of personnel & participants | Random outcome assessment | Incomplete outcome data | Selective outcome reporting |
|---|---|---|---|---|---|---|---|---|
| LITHIUM | ||||||||
| Caccamo et al., 2007 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Nocjar et al., 2007 | Unclear | Low | Unclear | Unclear | Low | Unclear | Low | Low |
| Rockenstein et al., 2007 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Fiorentini et al., 2010 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Toledo and Inestrosa, 2010 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Sy et al., 2011 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | High |
| Nunes et al., 2015 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Wilson et al., 2017 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Nery et al., 2014 | Unclear | Low | Unclear | Unclear | Unclear | Low | Low | Low |
| McBride et al., 2010 | Unclear | Low | Unclear | Unclear | Low | Unclear | Low | Low |
| RAPAMYCIN | ||||||||
| Spilman et al., 2010 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Majumder et al., 2011 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Halloran et al., 2012 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Majumder et al., 2012 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Lin et al., 2013 | Unclear | Low | Unclear | Unclear | Low | Unclear | Low | Low |
| Neff et al., 2013 | Unclear | Low | Unclear | Unclear | Low | Unclear | Low | Low |
| Wang et al., 2014 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Zhu et al., 2014 | Low | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Lin et al., 2015 | Unclear | Low | Unclear | Unclear | Low | Unclear | Low | Low |
| Wang et al., 2016 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Jahrling et al., 2017 | Unclear | Low | Unclear | Unclear | Low | Unclear | Low | Low |
| Zhang et al., 2017 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| RIFAMPICIN | ||||||||
| Umeda et al., 2016 | Unclear | Low | High | Unclear | High | Unclear | Low | Low |
| BOSUTINIB | ||||||||
| Lonskaya et al., 2013 | Unclear | Low | Unclear | Unclear | Low | Unclear | Low | High |
| M-CSF | ||||||||
| Boissonneault et al., 2009 | Unclear | Low | Unclear | Unclear | Low | Unclear | High | High |
| GM-CSF | ||||||||
| Boyd et al., 2010 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Low | High |
| METHYLENE bLUE | ||||||||
| Deiana et al., 2009 | Low | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Hochgräfe et al., 2015 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Medina et al., 2011 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | High |
| Stack et al., 2014 | Low | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| GGA | ||||||||
| Hoshino et al., 2013 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Sun et al., 2017 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Low |
| DANTROLENE | ||||||||
| Hopp et al., 2014 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Peng et al., 2012 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| Wu et al., 2015 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |
| PHENYLBUTYRIC ACID | ||||||||
| Wiley et al., 2011 | Unclear | Low | Unclear | Unclear | Low | Unclear | Low | Low |
| MINOCYCLINE | ||||||||
| Choi et al., 2007 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | High |
| Gibbs and Gibbs, 2013 | Unclear | Low | Unclear | Unclear | Unclear | Unclear | Low | Low |